Alise Taylor-Sindab

Alise Taylor-Sindab serves as a key procurement leader within the Administration for Strategic Preparedness and Response (ASPR), where she plays a central role in securing critical medical countermeasures and biomedical infrastructure to support national public health emergency preparedness. Her responsibilities encompass the full lifecycle of acquisition planning, solicitation, and contract award for high-priority pharmaceutical and biologic products essential to pandemic response, chemical threat mitigation, and biological incident readiness. She operates within the Department of Health and Human Services to ensure rapid, scalable procurement of life-saving therapeutics, vaccines, and diagnostic platforms aligned with federal strategic priorities. Taylor-Sindab collaborates with a broad network of pharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs) to deliver end-to-end supply chain resilience. While specific contractor names are not disclosed, her procurement patterns reflect sustained engagement with industry leaders capable of GMP-compliant large-scale production, sterile fill-finish capabilities, and cold chain logistics for biologics. Her working relationships emphasize technical capability, regulatory compliance, and surge manufacturing readiness over traditional vendor hierarchies. Her contracting activity is entirely non-set-aside, reflecting the urgent, mission-critical nature of ASPR’s mandate and the specialized scale required to meet national preparedness goals. This reflects a strategic prioritization of speed, capacity, and regulatory alignment over socioeconomic preferences, though it does not diminish broader federal small business initiatives elsewhere in HHS. Her primary focus lies in NAICS 325412—Pharmaceutical Preparation Manufacturing—where she procures injectables, antivirals, monoclonal antibodies, and other advanced therapeutics requiring stringent FDA oversight. Her expertise spans biopharmaceutical formulation, shelf-life validation, and emergency use authorization (EUA)-aligned procurement protocols, making her a pivotal figure in maintaining the nation’s biomedical defense posture.